Please assess the completion status of the following clinical trial:

Trial Title: Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female toddler between, and including, 18 and 24 months of age at the time of the booster vaccination.~* Subjects who received three doses of OPV as primary vaccination in the first year of life as per Chinese recommendations.~* Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP and/or Hib vaccine(s).~* Administration of immunoglobulins and/or any blood products within the three months preceding the booster vaccination, or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product~* Previous booster vaccination against poliomyelitis since the end of the primary vaccination series.~* History of poliomyelitis disease.~* History of seizures or progressive neurological disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* Major congenital defects or serious chronic illness.~The following condition is temporary or self-limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:~• Current febrile illness or axillary temperature \> 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- POLIORIX GROUP (Type: EXPERIMENTAL): Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete